Anavex Life Sciences Corp (AVXL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $86.53M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anavex Life Sciences Corp (AVXL) Financials: Revenue, Profit and Cash Flow
Anavex Life Sciences reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$46.38M, operating cash flow was -$39.04M and free cash flow was -$39.04M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $7.82M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $51.41M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $0 | N/A | N/A | N/A | N/A |
| Sep 2024 | $0 | N/A | N/A | N/A | N/A |
| Sep 2023 | $0 | N/A | N/A | N/A | N/A |
| Sep 2022 | $0 | N/A | N/A | N/A | N/A |
| Sep 2021 | $0 | N/A | N/A | N/A | N/A |
| Sep 2020 | $0 | N/A | N/A | N/A | N/A |
| Sep 2019 | $0 | N/A | N/A | N/A | N/A |
| Sep 2018 | $0 | N/A | N/A | N/A | N/A |
| Sep 2017 | $0 | N/A | N/A | N/A | N/A |
| Sep 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M | $22.26M | $13.34M | $10.67M | $7.25M |
| Operating income | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M | -$31.09M | -$29.11M | -$19.33M | -$15.68M | -$15.59M |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M |
| EBITDA | N/A | -$52.61M | N/A | N/A | N/A | -$30.81M | N/A | N/A | -$15.65M | -$15.42M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | $6.74M | -$6.48M | -$6.78M | -$10.84M | -$14.46M | -$12.51M | -$13.59M | -$14.27M | -$14.60M | -$12.62M | -$11.38M | -$12.66M |
| Net income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | -$11.20M | -$12.11M | -$11.62M | -$12.21M | -$10.55M | -$8.62M | -$10.15M |
Balance Sheet
As of Sep 2025, cash and equivalents of $102.58M were 98.8% of total assets of $103.81M, against total liabilities of $8.95M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | $161.62M | $34.54M | $25.33M | $26.21M | $27.84M | $9.50M |
| Current assets | $103.01M | $135.57M | $151.68M | $152.71M | $152.48M | $29.69M | $22.69M | $26.05M | $27.79M | $9.45M |
| Cash and equivalents | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M | $29.25M | $22.19M | $22.93M | $27.44M | $9.19M |
| Total liabilities | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M | $7.31M | $5.04M | $3.88M | $3.58M | $3.19M |
| Shareholder equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M | $27.24M | $20.29M | $22.32M | $24.25M | $6.31M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $120.14M | $128.77M | $132.99M | $103.81M | $102.43M | $117.14M | $124.04M | $135.57M | $141.53M | $144.52M | $148.07M | $154.39M |
| Total liabilities | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | $17.38M | $13.13M | $15.30M | $11.75M | $9.56M | $12.49M | $12.53M |
| Cash and equivalents | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | $115.77M | $120.78M | $132.19M | $138.76M | $139.39M | $143.76M | $151.02M |
| Shareholder equity | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | $99.76M | $110.92M | $120.26M | $129.78M | $134.96M | $135.57M | $141.85M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M | -$18.53M | -$12.58M | -$9.02M | -$9.24M |
| Capital expenditures | $0 | $0 | $0 | $4 | $4 | $4 | $0 | $0 | $0 | $3.02K |
| Free cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M | -$18.53M | -$12.58M | -$9.02M | -$9.24M |
| Share repurchases | N/A | N/A | N/A | $707.00K | $5.55M | $403.76K | $0 | N/A | N/A | N/A |
| Financing cash flow | $9.43M | $11.97M | $29.65M | $21.29M | $153.24M | $28.35M | $17.78M | $8.07M | $27.27M | $3.13M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -$5.86M | -$12.12M | -$6.66M | -$5.18M | -$11.66M | -$7.32M | -$5.85M | -$7.65M |
| Free cash flow | N/A | -$7.15M | -$8.60M | -$12.46M | -$5.86M | -$12.12M | -$6.66M | -$5.18M | -$11.66M | -$7.32M | -$5.85M | -$7.65M |
Frequently Asked Questions About AVXL
What is Anavex Life Sciences' annual revenue?
Anavex Life Sciences reported revenue of $0 for the fiscal year ended Sep 30, 2025.
Is Anavex Life Sciences profitable?
No. Anavex Life Sciences reported net income of -$46.38M for the fiscal year ended Sep 30, 2025.
How much free cash flow does AVXL generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$39.04M minus capital expenditures of $0 produced free cash flow of -$39.04M.
How much debt does Anavex Life Sciences have?
The balance sheet dated Sep 30, 2025 reported cash and equivalents of $102.58M.
AVXL pages: Overview, Earnings, Forecast, Financials